NCT Number: NCT05794464
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Ostrava, Moravian-Silesian Region, 70852, Czechia
Location status: Recruiting
David Stejskal, prof.,MD,PhD,EurChem
SUB_INVESTIGATOR
Jan Václavík, prof.,MD,PhD,FESC
SUB_INVESTIGATOR
Jiří Hynčica
CONTACT
0042059737 ext. 2587
Jiří Plášek, MD,PhD,FESC
PRINCIPAL_INVESTIGATOR
The aim of the study is to sample SN before and after catheter ablation (CA) for atrial fibrillation (Afib) to predict the recurrence after CA. Also, the uric acid/albumin ratio will be assessed as a marker of Afib recurrence. Since the uric acid/albumin ratio has been shown to be predictive of Afib in patients with myocardial infarction moreover incidence of atrial fibrillation is higher in patients with gout. As a side branch marker for silent brain injury, neuron-specific enolase (NSE) and protein S100B will be evaluated. NSE showed in small trials a significant increase after catheter ablation, as well as S100B. The prognostic power is not clear yet. From the systematic review, the most powerful predictors seem to be N-terminal (NT)-prohormone B-type natriuretic peptide (NT-Pro-BNP/BNP), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and Carboxy-terminal telopeptide of collagen type I. Biomarkers are divided into 3 main types: congestion, inflammation, and renal function.
Patients will be enrolled before catheter ablation/electrical cardioversion for Afib after signing IS, and the blood sampling will be performed the day before and the day after catheter ablation. In the electric cardioversion arm, the blood sampling will be performed before electrical cardioversion and 2h after the cardioversion before discharge.
Patients will be followed for recurrency - all patients will have a 24-hour ECG Holter and External loop recorder (MDT) for two weeks after the three months of the blanking period. Clinical outpatient control will ensue in the 4th, eighth,12, and 24 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
Time frame: 24 months
Atrial fibrillation recurrence based on secretoneurin levels will be assessed
Time frame: 24 months
Brain injury will be detected using serum protein S100B and neuron specific enolase.
Contact information is provided by the study sponsor or research team.
University Hospital Ostrava
Other
Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06249269
Arrhythmias, Cardiac, Atrial Fibrillation
Calgary, Alberta, Canada
View Trial DetailsNCT06557616
Arrhythmias, Cardiac, Atrial Fibrillation
Bydgoszcz, Poland
View Trial DetailsNCT06056557
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial DetailsNCT05883631
Arrhythmia, Arrhythmias, Cardiac
Birmingham, Alabama, United States
View Trial Details